Dare Bioscience Inc
(DARE)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,155 | -6,755 | -30,161 | -25,104 | -16,805 |
| Depreciation Amortization | 48 | 11 | 38 | 28 | 19 |
| Accounts receivable | -28 | -68 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -1,476 | 655 | 1,358 | 2,959 | 4,513 |
| Other Working Capital | -2,283 | -1,499 | -10,427 | -7,789 | -7,375 |
| Other Operating Activity | 3,675 | 843 | 336 | -773 | -3,057 |
| Operating Cash Flow | $6,092 | $-6,813 | $-38,857 | $-30,678 | $-22,704 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -293 | -7 | -629 | -22 | N/A |
| Investing Cash Flow | $-293 | $-7 | $-629 | $-22 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 601 | 601 | N/A |
| Debt Repayment | -269 | -200 | -334 | -134 | N/A |
| Common Stock Issued | 398 | 214 | 15,370 | 9,860 | 1,752 |
| Financing Cash Flow | $129 | $14 | $15,637 | $10,328 | $1,752 |
| Exchange Rate Effect | -25 | -39 | -10 | -68 | -53 |
| Beginning Cash Position | 10,811 | 10,811 | 34,670 | 34,670 | 34,670 |
| End Cash Position | 16,715 | 3,966 | 10,811 | 14,229 | 13,664 |
| Net Cash Flow | $5,904 | $-6,846 | $-23,859 | $-20,440 | $-21,006 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,092 | -6,813 | -38,857 | -30,678 | -22,704 |
| Capital Expenditure | -293 | -7 | -629 | -22 | N/A |
| Free Cash Flow | 5,799 | -6,820 | -39,486 | -30,700 | -22,704 |